These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 17881666)
1. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Gelinck LB; Teng YK; Rimmelzwaan GF; van den Bemt BJ; Kroon FP; van Laar JM Ann Rheum Dis; 2007 Oct; 66(10):1402-3. PubMed ID: 17881666 [No Abstract] [Full Text] [Related]
2. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Arad U; Tzadok S; Amir S; Mandelboim M; Mendelson E; Wigler I; Sarbagil-Maman H; Paran D; Caspi D; Elkayam O Vaccine; 2011 Feb; 29(8):1643-8. PubMed ID: 21211590 [TBL] [Abstract][Full Text] [Related]
3. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. van Assen S; Holvast A; Benne CA; Posthumus MD; van Leeuwen MA; Voskuyl AE; Blom M; Risselada AP; de Haan A; Westra J; Kallenberg CG; Bijl M Arthritis Rheum; 2010 Jan; 62(1):75-81. PubMed ID: 20039396 [TBL] [Abstract][Full Text] [Related]
4. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Kapetanovic MC; Saxne T; Nilsson JA; Geborek P Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801 [TBL] [Abstract][Full Text] [Related]
5. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Oren S; Mandelboim M; Braun-Moscovici Y; Paran D; Ablin J; Litinsky I; Comaneshter D; Levartovsky D; Mendelson E; Azar R; Wigler I; Balbir-Gurman A; Caspi D; Elkayam O Ann Rheum Dis; 2008 Jul; 67(7):937-41. PubMed ID: 17981914 [TBL] [Abstract][Full Text] [Related]
6. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. Salemi S; Picchianti-Diamanti A; Germano V; Donatelli I; Di Martino A; Facchini M; Nisini R; Biselli R; Ferlito C; Podestà E; Cappella A; Milanetti F; Rossi F; Amodeo R; Tabacco F; Di Rosa R; Laganà B; D Amelio R Clin Immunol; 2010 Feb; 134(2):113-20. PubMed ID: 19846344 [TBL] [Abstract][Full Text] [Related]
7. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Belmonte Serrano MA; Pincus T Rheumatology (Oxford); 2010 Sep; 49(9):1795-6; author reply 1796-7. PubMed ID: 20484342 [No Abstract] [Full Text] [Related]
8. [Pharmacotherapy of rheumatoid arthritis in the era of genetically engineered biological preparations]. Nasonov EL Ter Arkh; 2007; 79(5):5-8. PubMed ID: 17672066 [No Abstract] [Full Text] [Related]
9. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. Kaine JL; Kivitz AJ; Birbara C; Luo AY J Rheumatol; 2007 Feb; 34(2):272-9. PubMed ID: 17304653 [TBL] [Abstract][Full Text] [Related]
10. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents. Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227 [No Abstract] [Full Text] [Related]
11. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis. Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487 [TBL] [Abstract][Full Text] [Related]
12. Infliximab for rheumatoid arthritis in a patient with tuberculosis. Matsumoto T; Tanaka T; Kawase I N Engl J Med; 2006 Aug; 355(7):740-1. PubMed ID: 16914717 [No Abstract] [Full Text] [Related]
13. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Elkayam O; Bashkin A; Mandelboim M; Litinsky I; Comaheshter D; Levartovsky D; Mendelson E; Wigler I; Caspi D; Paran D Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078 [TBL] [Abstract][Full Text] [Related]
14. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Rehnberg M; Brisslert M; Amu S; Zendjanchi K; Håwi G; Bokarewa MI Arthritis Res Ther; 2010; 12(3):R111. PubMed ID: 20529331 [TBL] [Abstract][Full Text] [Related]
15. TNF-alpha antagonists and other recombinant proteins for the treatment of rheumatoid arthritis. Brasington R J Hand Surg Am; 2009 Feb; 34(2):349-50. PubMed ID: 19135810 [No Abstract] [Full Text] [Related]
16. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C; Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098 [TBL] [Abstract][Full Text] [Related]